To explore the effect of smart app and wearable-based lifestyle intervention managementon vascular health, comparing different exercise with the improvement of vasculararterial stiffness. The accuracy and consistency evaluation of smart wearable devices inscreening for vascular health risks were also discussed.
This study intends to carry out a randomized controlled trial to dynamically monitor a
variety of cardiovascular parameters in people with high risk of vascular health, using
wearable devices and artificial intelligence-assisted health management platform, and
provide intelligent lifestyle intervention programs with different exercise.By observing
the improvement of vascular health in the study population, the management effect of
intelligent lifestyle intervention on high-risk groups of vascular health was evaluated.
It is expected that through comprehensive lifestyle intervention based on smart wearable
devices, early prevention and control of arteriosclerosis can be achieved, the level of
hospital health management will be improved, and more physical health and health economic
benefits will be obtained.
Behavioral: Regular exercise
Based on the study participant's status and exercise assessment, the investigators
prescribe moderate-intensity aerobic exercise combined with resistance exercise. Before
each exercise, preparatory activities (10min), 20-30min moderate-intensity aerobic
exercise, finishing activities (10min) at the end, 5 days/week, for 12 weeks, and at the
same time, choose non-consecutive 3 days of resistance training in 5 aerobic training
sessions to increase resistance training (choose 1~2 muscle groups each time, 4~5
movements, repeat each action 8~12 times, repeat 2~3 sets)
Behavioral: Baduanjin
A professional therapist instructed the participants to learn and train Baduanjin before
the intervention, and a standardized Baduanjin exercise program included eight postures,
each training time was about 50 minutes (including 10 min of warm-up, 2 times of
Baduanjin, and 10 min of relaxation), 5 days/week, a total of 12 weeks
Inclusion Criteria:
1. Age: ≥ 18 years old and < 60 years old;
2. cfPWV>10m/s;
3. Those who have 1 intelligent communication device and can use it proficiently
(Android mobile phone is preferred);
4. People who have lived and/or worked relatively steadily in the past 6 months;
5. Signed informed consent.
Exclusion Criteria:
1. Moderate to severe obesity (≥30kg/m^2);
2. Acute myocardial infarction, acute tachyarrhythmia, pulmonary edema, severe aortic
stenosis and other serious circulatory respiratory diseases and acute cardiovascular
and cerebrovascular diseases;
3. severe essential hypertension (systolic blood pressure ≥180mmHg and/or diastolic
blood pressure ≥110mmHg) or poorly controlled essential hypertension;
4. Patients with secondary hypertension, acute hypertension, subacute hypertension and
hypertensive encephalopathy;
5. Significant arrhythmia (atrial fibrillation, etc.);
6. Patients with atherosclerotic cardiovascular diseases, such as coronary heart
disease, severe peripheral atherosclerotic diseases, etc.;
7. Type 1 diabetes, uncontrolled type 2 diabetes or other diseases affecting
carbohydrate metabolism;
8. Severe stenosis of the carotid and/or femoral arteries (resulting in significant
abnormalities in the blood flow spectrum); Those who have anatomical abnormalities
of the aorta and major branches and cannot complete PWV detection;
9. Cancer and other major comorbidities affecting arterial blood pressure;
10. Those who are unable to exercise due to fractures, joint instability and other
physical diseases or diseases affecting the locomotor system;
11. Those who have involuntary physical movements due to mental illness, epilepsy or
other diseases;
12. Those who have a pacemaker installed;
13. Pregnant/trying to conceive;
14. Patients with allergies, limb trauma or skin diseases who cannot cooperate with the
completion of ABI and baPWV index examinations;
15. Those who have undergone or plan to have bariatric surgery in the next 12 months;
16. Those who have participated in other clinical studies in the past 3 months;
17. Refusal to sign informed consent.
Not Provided
Yifan Wu
01088398069
wuyifan1127@126.com
Xue Feng, Principal Investigator
Chinese Academy of Medical Sciences, Fuwai Hospital